Genetics and the placebo effect: the placebome

Area of Science:

• Pharmacogenomics
• Neuroscience
• Clinical Trial Design

Background:

• Placebo responses are critical in randomized clinical trials (RCTs) and clinical outcomes.
• Neurophysiological studies have identified neurotransmitter pathways mediating placebo effects.
• Genetic variations may influence individual placebo response.

Purpose of the Study:

• To review evidence on genes influencing placebo response (the 'placebome').
• To examine potential interactions between placebo and drug molecular pathways.
• To discuss implications for RCT design and clinical care.

Main Methods:

• Review of existing placebo studies and RCT data.
• Identification of candidate genes within the 'placebome'.
• Analysis of evidence for placebo-drug pathway interactions.

Main Results:

• Genetic variations in neurotransmitter pathways can modify placebo effects.
• Potential for genetic screening to identify placebo responders.
• Placebo-drug interactions require consideration in trial design.

Conclusions:

• The study of genomic influences on placebo response is an emerging field.
• Genetic screening may optimize RCTs and personalize therapeutic care.
• Understanding the 'placebome' is crucial for future clinical research and practice.